4/A//SEC Filing
PATOU GARY 4/A
Accession 0000950170-23-070912
CIK 0001582313other
Filed
Dec 14, 7:00 PM ET
Accepted
Dec 15, 9:50 PM ET
Size
5.7 KB
Accession
0000950170-23-070912
Insider Transaction Report
Form 4/AAmended
PATOU GARY
Director
Transactions
- Sale
Common Shares
2023-12-14$41.05/sh−7,598$311,898→ 4,902 total(indirect: See Note)
Footnotes (3)
- [F1]Pursuant to the terms of a Lock-Up Agreement executed by the Reporting Person in favor of the underwriters of the Company's follow-on public offering in November 2023, the Reporting Person is permitted to transfer up to 22,000 common shares beneficially owned prior to November 29, 2023 or received upon the exercise of an option to purchase common shares during the lock-up period.
- [F2]The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $41.00 to $41.06, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
- [F3]By Gary & Karen Barbara Patou TTEE Patou Family Trust FBO Gary Patou Karen Barbara Patou.
Documents
Issuer
Xenon Pharmaceuticals Inc.
CIK 0001582313
Entity typeother
Related Parties
1- filerCIK 0001283535
Filing Metadata
- Form type
- 4/A
- Filed
- Dec 14, 7:00 PM ET
- Accepted
- Dec 15, 9:50 PM ET
- Size
- 5.7 KB